Navigation Links
Optimer Pharmaceuticals and Astellas Receive Positive Opinion from CHMP for European Approval of DIFICID™
Date:9/23/2011

ease," said Pedro Lichtinger, President and CEO of Optimer.

The European Commission generally follows the recommendations of the CHMP and delivers its final decision within three months of the CHMP opinion.

Important Safety Information for DIFICID

  • DIFICID should not be used for systemic infections
  • Only use DIFICID for infection proven or strongly suspected to be caused by C. difficile. Prescribing DIFICID in the absence of a proven or strongly suspected C. difficile infection is unlikely to provide benefit to the patient and increases the risk of the development of drug resistant bacteria
  • The most common adverse reactions are nausea (11%), vomiting (7%), abdominal pain (6%), gastrointestinal hemorrhage (4%), anemia (2%), and neutropenia (2%)

About CDAD

Clostridium difficile-associated diarrhea (CDAD) has become a significant medical problem in hospitals, long-term care facilities and in the community. CDAD is a serious illness resulting from infection of the inner lining of the colon by C. difficile bacteria, which produce toxins that cause inflammation of the colon, severe diarrhea and, in the most serious cases, death. Patients typically develop CDAD from the use of broad-spectrum antibiotics that disrupt normal gastrointestinal (gut) flora, possibly allowing C. difficile bacteria to flourish. Older patients in particular are at risk for CDAD, potentially because of a weakened immune system or the presence of underlying disease. Approximately two-thirds of CDAD patients are 65 years of age or older.

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer developed and is commercializing DIFICID™ (fidaxomicin) tablets
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Optimer to Provide DIFICID™ Launch Update at Morgan Stanley Global Healthcare Conference
2. Optimer Pharmaceuticals DIFICID Featured in 11 Presentations at 51st ICAAC
3. Optimer Pharmaceuticals to Present at September 2011 Investor Conferences
4. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
5. Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimers DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin
6. Optimer Pharmaceuticals Reports Second Quarter 2011 Financial Results
7. Optimer Launches DIFICID™ (fidaxomicin) Tablets for Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) in Patients 18 Years of Age and Older
8. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
9. Optimer Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference
10. Optimer Pharmaceuticals Reports First Quarter 2011 Financial Results
11. Optimer Pharmaceuticals Expands Senior Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , July 31, 2014 AFFiRiS AG ... York results of AFF008, a Phase I clinical ... the first therapy against the protein alpha-synuclein, a promising Parkinson,s ... J. Fox Foundation for Parkinson,s Research (MJFF) supported the study ... press conference on the impact a disease-modifying therapy would have ...
(Date:7/31/2014)... July 31, 2014 For the first time, ... the implantation of the SynCardia temporary Total Artificial Heart ... video posted on the Journal of Visualized Experiments website. ... the paper on the SynCardia Total Artificial Heart implantation ... accompanies "Implantation of the SynCardia Total Artificial Heart," a ...
(Date:7/31/2014)... NEW YORK , July 31, 2014 ... developing better, faster and affordable treatments for tuberculosis (TB), ... Senior Vice President, Market Access. Ms. Robertson joins the ... the company,s business in Sub-Saharan Africa and ... will oversee the TB Alliance,s efforts to ensure beneficial ...
Breaking Medicine Technology:First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 3First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 4How to Implant the SynCardia Total Artificial Heart Detailed in Peer Reviewed Paper and Matching Video 2How to Implant the SynCardia Total Artificial Heart Detailed in Peer Reviewed Paper and Matching Video 3TB Alliance Names Elana Robertson Senior Vice President, Market Access 2TB Alliance Names Elana Robertson Senior Vice President, Market Access 3
... Rapid Fire Marketing (Pink Sheets: RFMK ) announced ... Manufacturer to begin the development of the Pocket Puffer and the ... all specifications are met, the manufacturing facility will set up the ... a patent of the new device once complete and approved. ...
...  Ameritox, the national leader in pain medication monitoring, ... against San Diego-based Millennium Laboratories seeking damages, injunctive ... and unfair trade practices.  The Ameritox filing alleges ... in violations of the Lanham Act, unfair competition ...
Cached Medicine Technology:Rapid Fire Marketing Funds Development of Second Generation Vapor Inhaler 2Ameritox Files Amended Complaint Against Millennium Laboratories For Injunctive Relief, Declaratory Relief and Damages 2Ameritox Files Amended Complaint Against Millennium Laboratories For Injunctive Relief, Declaratory Relief and Damages 3
(Date:7/31/2014)... July 31, 2014 Ticket Down ... Cup Finals tickets at the Sun Life Stadium in ... Champions Cup is now underway. Residents and diehard soccer fans ... to watch the Guinness International Champions Cup final in person ... competing in the tournament have been split into two groups ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Ce-Classes.com ... continues to help healthcare agencies to pass inspections ... and agencies meet their accreditation and state ... based training. , Healthcare administrators can monitor ... clicks of the mouse. Courses can be developed ...
(Date:7/31/2014)... Zensah®, a leading Miami based compression apparel company, ... , designed to help target tennis elbow, elbow tendonitis, ... for summer. The compression elbow sleeve is now available ... Zensah® fabric, the elbow sleeve is made ... no-slip cuff to ensure it stays in place, even ...
(Date:7/31/2014)... To further educate the public, The Rothenberg ... safety information regarding leaving children in hot vehicles: , ... consequences. Because a child’s body can heat up three ... children alone in a hot vehicle puts them at ... Statistics of Children Left Alone in a Car , ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Most mommy ... journals. Mommylish’s main purpose is to attract all mothers ... targeted to a particular group; whether its high fashion ... she realized that everything on the Internet was so ... information on a particular topic and then search Google ...
Breaking Medicine News(10 mins):Health News:Guinness International Champions Cup Finals Tickets in Miami, FL Available at Ticket Down 2Health News:Guinness International Champions Cup Finals Tickets in Miami, FL Available at Ticket Down 3Health News:Company Helps Healthcare Agencies to Pass Inspections and Audits 2Health News:Company Helps Healthcare Agencies to Pass Inspections and Audits 3Health News:Compression Elbow Sleeve Provides Relief From Elbow Pain to Golfers and Tennis Players 2Health News:Compression Elbow Sleeve Provides Relief From Elbow Pain to Golfers and Tennis Players 3Health News:The Rothenberg Law Firm LLP Teams Up with Local Philadelphia TV Stations to Promote Awareness of the Dangers of Leaving Children Unattended in a Hot Vehicle 2Health News:The Rothenberg Law Firm LLP Teams Up with Local Philadelphia TV Stations to Promote Awareness of the Dangers of Leaving Children Unattended in a Hot Vehicle 3Health News:Mommylish Launches Its Website 2
... VANCOUVER, May 15 /PRNewswire-FirstCall/ - CRH Medical Corporation,(CRM:TSX-V) announced ... in Bay Shore, Long Island. This Center is the ... many new markets that CRH has targeted for,expansion. The ... in 2008 bringing the Company,s total number of Centers ...
... N.Y., May 15 Two nutrients found in,certain fruits ... are lutein and zeaxanthin and they are found in ... show that lutein and zeaxanthin not only help prevent ... healthy eyes. For,example, they can improve photostress recovery under ...
... of Global Unified Worklist ... SEATTLE, May 15 Compressus, leaders in ... APC, of,Seattle, announced today an agreement to implement ... data management systems.,The implementation, which will include eight ...
... in mouse model hint of new treatment strategies for the ... polyunsaturated fat, the kind often found in baked and fried ... , The finding by University of California, Los Angeles, scientists ... a mouse model that closely mimics human cancer. , The ...
... PRO-DEX, INC. (Nasdaq:,PDEX) invites shareholders and investors to listen ... quarter financial results, and a discussion,of the outlook for ... be broadcast live over the Internet on,Thursday, May 15, ... accessed by,visiting the Company,s website at http://www.pro-dex.com . ...
... 15 ev3 Inc. (Nasdaq:,EVVV) today announced that Pat ... to present at the 2008 FBR Capital Markets,Spring Investor ... Eastern,Time (1:20 p.m. Central Time and 11:20 a.m. Pacific ... be held at the Grand Hyatt,Hotel, located at 109 ...
Cached Medicine News:Health News:CRH Medical Corporation opens Center in New York 2Health News:Lutein and Zeaxanthin Improve Sports Vision for Athletes 2Health News:Compressus Announces Seattle Radiologists Interoperability Implementation 2Health News:Compressus Announces Seattle Radiologists Interoperability Implementation 3Health News:Lowering Dietary Fat May Help Prevent Prostate Cancer 2Health News:Pro-Dex, Inc. Announces Fiscal 2008 Third Quarter Financial Results Conference Call and Webcast 2
... The TheraSeed® Pd-103 implant is a ... and remarkable visibility that makes TheraSeed® treatment ... You can be confident that every TheraSeed® ... management services which is required by clinicians ...
... BrachyStar® Needle is designed to help you ... clinically effective brachytherapy procedure. All needles are ... and polished surfaces for smooth entry and ... and sizes assures an ideal match with ...
... is a combination of innovative design, consistently ... BrachySource I-125 implant an ideal choice for ... that every BrachySource I-125 implant order is ... is required by clinicians who must meet ...
... temporary internal drainage from the ureteropelvic junction ... stricture. The segment with no sideports prevents ... preventing ingrowth of the ureteral wall to ... Intended for one-time use. CAUTION: Periodic evaluation ...
Medicine Products: